What is the recommended management for a genital herpes simplex virus type 2 (HSV‑2) outbreak?

Management of HSV-2 Outbreaks

For an acute HSV-2 outbreak, initiate oral antiviral therapy immediately—preferably valacyclovir 500 mg twice daily for 5 days—starting at the first sign of prodrome or within 24 hours of lesion onset to maximize clinical benefit. 1

First Clinical Episode vs. Recurrent Outbreak: Treatment Selection

First Clinical Episode (Initial Infection)

• Treat for 7–10 days with one of the following CDC-recommended regimens 2, 1:
  • Valacyclovir 1 g orally twice daily (most convenient dosing) 1
  • Acyclovir 400 mg orally three times daily 2, 1
  • Famciclovir 250 mg orally three times daily 2
• Extend treatment beyond 10 days if lesions have not completely healed, as large or severe ulcers may require up to 2 weeks 1
• For severe disease requiring hospitalization (disseminated infection, encephalitis, pneumonitis, hepatitis, or inability to tolerate oral medication), administer acyclovir 5–10 mg/kg IV every 8 hours for 5–7 days or until clinical resolution 2, 1

Recurrent Outbreaks (Episodic Therapy)

• Initiate treatment during prodrome or within 24 hours of lesion appearance when viral replication peaks 2, 1
• Standard 5-day regimens 2, 1:
  • Valacyclovir 500 mg orally twice daily (preferred for convenience) 1
  • Acyclovir 800 mg orally twice daily 1
  • Acyclovir 400 mg orally three times daily 1
  • Famciclovir 125 mg orally twice daily 1
• Provide patients with a prescription or medication supply to self-initiate at the first prodromal symptom, as delaying treatment beyond 24 hours significantly reduces efficacy 2, 1

Suppressive Therapy: When and How

Indications for Daily Suppressive Therapy

• Offer suppressive therapy to all patients with ≥6 recurrences per year, as it reduces recurrence frequency by ≥75% 2, 1
• Also consider suppressive therapy for patients in serodiscordant relationships to reduce transmission risk, even if recurrences are infrequent 2, 1

Suppressive Regimens

• Valacyclovir 500 mg orally once daily (for patients with <10 recurrences/year) 1
• Valacyclovir 1 g orally once daily (for patients with ≥10 recurrences/year or those seeking maximal viral suppression) 1
• Acyclovir 400 mg orally twice daily (safety documented up to 6 years) 2, 1
• Famciclovir 250 mg orally twice daily (safety documented up to 1 year) 2, 1

Duration and Reassessment

• After 1 year of continuous suppressive therapy, discontinue temporarily to reassess recurrence frequency, as the natural history often shows declining recurrence rates over time 2, 1

Special Populations and Scenarios

HIV-Coinfected Patients

• Use valacyclovir 500 mg orally twice daily (not once daily) for suppressive therapy in HIV-positive patients to achieve adequate viral control 1
• Suppressive therapy does NOT effectively reduce HSV-2 transmission risk in HIV-coinfected individuals, so additional preventive measures remain essential 1
• Daily suppressive therapy reduces HIV RNA concentrations in plasma and genital secretions, though its impact on HIV transmission remains uncertain 1

Immunocompromised Patients (Non-HIV)

• Higher oral acyclovir dosing (400 mg three to five times daily) is required until clinical resolution 1
• Suspect acyclovir resistance if lesions fail to improve within 7–10 days of appropriate therapy 1
• For confirmed resistance, IV foscarnet 40 mg/kg every 8 hours is the treatment of choice 1
• Topical cidofovir, trifluridine, or imiquimod may be used for external resistant lesions, requiring prolonged application (≈21–28 days) 1

Pregnancy

• Initiate antiviral prophylaxis at 36 weeks gestation and continue until delivery in women with a history of genital herpes to reduce term-time recurrences and cesarean delivery rates 1
• Perform cesarean delivery if any of the following are present at labor onset 1:
  • Suspected or confirmed first-episode genital herpes
  • First episode occurring <6 weeks before delivery
  • Prodrome or visible lesions at labor onset
• Oral acyclovir may be used during pregnancy for first episodes or recurrences, though safety data remain limited 1

HSV-2 Meningitis

• For first-episode HSV-2 meningitis, initiate acyclovir 10 mg/kg IV every 8 hours until fever and headache resolve, then transition to oral valacyclovir 1 g three times daily to complete a 14-day course 1
• For recurrent HSV-2 meningitis, an entirely oral antiviral regimen may be used 1
• Obtain cerebrospinal fluid HSV PCR in all suspected cases 1

Herpes Proctitis

• For first-episode herpes proctitis, use acyclovir 400 mg orally five times daily for 10 days (higher dosing and longer duration than standard genital herpes) 1

Renal Function Monitoring

• Assess renal function before starting and during antiviral therapy; adjust dosing frequency or total daily dose according to creatinine clearance to avoid toxicity 1

Critical Pitfalls to Avoid

What NOT to Do

• Do NOT use topical acyclovir—it is substantially less effective than oral therapy and does not improve systemic symptoms, viremia, or viral shedding from cervix, urethra, or pharynx 2, 1
• Do NOT use valacyclovir 500 mg once daily in patients with ≥10 recurrences per year—it is less effective than higher-dose regimens 1
• Do NOT delay episodic therapy beyond 24 hours of lesion onset—efficacy drops significantly after the initial viral replication peak 2, 1
• Do NOT use valacyclovir 8 g/day in immunocompromised patients—it is associated with hemolytic uremic syndrome/thrombotic thrombocytopenic purpura 3

Transmission Prevention Counseling

Essential Patient Education Points

• Abstain from all sexual activity when lesions or prodromal symptoms are present 2, 1
• Inform all sexual partners about the HSV-2 diagnosis 2, 1
• Use condoms during all sexual encounters with new or uninfected partners, though condoms do not completely eliminate transmission risk 2, 1
• Asymptomatic viral shedding can occur even on suppressive therapy, posing ongoing transmission risk 2, 1
• HSV-2 causes more frequent asymptomatic shedding than HSV-1, particularly during the first 12 months after infection 1
• Neonatal transmission risk is 25–44% with a primary episode at delivery versus ≈1% with recurrent infection 1
• Antiviral medications control symptoms but do not eradicate the virus or prevent all recurrences 2, 1

Suppressive Therapy for Transmission Reduction

• Suppressive therapy reduces transmission to uninfected partners in HIV-negative heterosexual couples but does not eliminate risk 1
• The mechanism is through suppression of viral shedding, applicable across all populations 2

Antiviral Resistance Management

When to Suspect Resistance

• Suspect resistance if lesions fail to improve within 7–10 days of appropriate therapy 1
• Resistance is uncommon in immunocompetent hosts but more frequent in immunocompromised patients, especially those with HIV on long-term suppressive therapy 1

Confirmation and Treatment

• Confirm resistance with viral culture and susceptibility testing 1
• IV foscarnet 40 mg/kg every 8 hours is the treatment of choice for confirmed resistant HSV 1
• Topical cidofovir, trifluridine, or imiquimod may be used for external lesions 1
• Helicase-primase inhibitors (e.g., pritelivir) are under investigation for resistant HSV-2 in immunocompromised patients but are not yet FDA-approved 1